0001209191-23-001995.txt : 20230105
0001209191-23-001995.hdr.sgml : 20230105
20230105173902
ACCESSION NUMBER: 0001209191-23-001995
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doerfler Douglas
CENTRAL INDEX KEY: 0001874482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 23512632
MAIL ADDRESS:
STREET 1: C/O MAXCYTE, INC.
STREET 2: 22 FIRSTFIELD ROAD, SUITE 110
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-03
0
0001287098
MAXCYTE, INC.
MXCT
0001874482
Doerfler Douglas
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
1
1
0
0
President and CEO
Common Stock
2023-01-03
4
M
0
10613
0.04
A
343810
D
Common Stock
2023-01-03
4
S
0
10613
5.13
D
333197
D
Common Stock
2023-01-04
4
M
0
9153
0.04
A
342350
D
Common Stock
2023-01-04
4
S
0
9153
5.07
D
333197
D
Common Stock
2023-01-05
4
M
0
10234
0.04
A
343431
D
Common Stock
2023-01-05
4
S
0
10234
5.04
D
333197
D
Employee Stock Option (right to buy)
0.04
2023-01-03
4
M
0
10613
0.00
D
2024-11-11
Common Stock
10613
434467
D
Employee Stock Option (right to buy)
0.04
2023-01-04
4
M
0
9153
0.00
D
2024-11-11
Common Stock
9153
425314
D
Employee Stock Option (right to buy)
0.04
2023-01-05
4
M
0
10234
0.00
D
2024-11-11
Common Stock
10234
415080
D
The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
This option is fully vested and exercisable.
/s/ Brian F. Leaf, attorney-in-fact
2023-01-05